Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals (formerly Bayer Schering Pharma AG)-Deals & Alliances Report | Mar 2011 | £380 | 100% |
| Bayer AG - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 98% |
| Bayer AG - Medical Equipment Deals and Alliances Profile |
Jul 2009 | £160 | 94% |
| Bayer AG – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 93% |
| Bayer HealthCare AG - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 87% |
| Veterinary Vaccines | Feb 2011 | £2,845 | 86% |
| Imaging Agents | Feb 2011 | £2,845 | 86% |
| Mergers and Aquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
Apr 2009 | £995 | 85% |
| MorphoSys AG – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 83% |
| Hepatitis C Virus And Therapeutics | Apr 2009 | £2,500 | 81% |
| Multiple Sclerosis Therapeutics | Apr 2010 | £2,500 | 80% |
| Key Trends in Offshoring Pharmaceutical R&D Company strategies, emerging markets and impact on ROI |
Mar 2009 | £2,425 | 77% |
| Hepatitis C Virus and Therapeutics A Global Update of Market Trends & Opportunities |
Nov 2009 | £1,895 | 77% |
| Acute Coronary Syndrome | Apr 2010 | £2,180 | 77% |
| Syndax Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 75% |
| Endo Pharmaceuticals Holdings Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 73% |
| Chronic Obstructive Pulmonary Disease | Feb 2010 | £2,180 | 72% |
| Anti-CD20 Monoclonal Antibodies | Jul 2010 | £2,500 | 71% |
| Bayer Healthcare Strategic Analysis Profile |
Feb 2008 | £500 | 71% |
| Pharmaceutical Pricing Compendium A practical guide to the pricing and reimbursement of medicines |
Mar 2003 | £125 | 71% |
| Bayer HealthCare AG Market Share Analysis |
Oct 2010 | £630 | 70% |
| Understanding the Global Biotech Industry The New 'Engine' of the Global Economy |
Jan 2009 | £190 | 70% |
| Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
Jan 2009 | £945 | 69% |
| Imaging Agents A Worldwide Market Review |
Nov 2009 | £1,895 | 69% |
| Testosterone Replacement Therapy (TRT) | Apr 2011 | £2,910 | 69% |
| Germany Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2012 | Mar 2009 | £1,580 | 69% |
| Radiopharmaceuticals A US and European Market Analysis |
Nov 2009 | £1,895 | 68% |
| Rheumatoid Arthritis Therapeutics | Feb 2010 | £2,500 | 68% |
| Contraceptives | Oct 2010 | £2,845 | 68% |
| Analysis of Oncology Deals Trends in Deal Structures and Valuations |
Dec 2009 | £2,243 | 68% |
